Ibrutinib
- PDF / 169,440 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 8 Downloads / 186 Views
1
S
Atrial fibrillation: case report In a retrospective, cohort study of 202 patients with chronic lymphocytic leukaemia (CLL), who received ibrutinib at a clinic in the USA between November 2013 and June 2017, an approximately 79-year-old patient [sex not stated] was described, who developed atrial fibrillation during treatment with ibrutinib for CLL. The patient, who had relapse/refractory CLL, had started receiving ibrutinib [route and dosage not stated] at the age of 78 years. Following 12 months of the therapy (at an approximate age of 79 year), the patient developed atrial fibrillation secondary to ibrutinib. Therefore, ibrutinib was stopped, and the patient subsequently experienced rapid progression of the CLL [outcome of ADR not stated]. Author comment: "Rapid progression of disease was observed in. . .one patient who discontinued due to toxicity (atrial fibrillation)." Hampel PJ, et al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leukemia and Lymphoma 60: 2712-2719, No. 11, 2019. Available from: URL: 803439026 http://doi.org/10.1080/10428194.2019.1602268 - USA
0114-9954/19/1783-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Dec 2019 No. 1783
Data Loading...
